Loading
Latest filing published 03 Dec 2025 for Sonnet BioTherapeutics Holdings, Inc..
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
John K. Cini (senior executive) discloses dealings in Sonnet BioTherapeutics Holdings, Inc. to SEC (Form 4). In total, 10 filings cover trades dated from 1 April 2020 to 2 December 2025.
The filings describe grants, exercises and other transfers rather than trades on the open market. Compensation-driven entries like these are tracked, but they say little about how insiders judge the share price.
The latest filing, published on 3 December 2025, reports a transaction in Sonnet BioTherapeutics Holdings, Inc. The median gap between a trade and its publication by SEC (Form 4) is 6 days. The legal deadline for a Form 4 is two business days after the transaction. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
7 of 7 declarations